COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Methods

Variants of concern

RCTs

Vaccine types

Overall results (Last update:2021-10-22)

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04649151
ModernaTX
Ali K, N Engl J Med, 2021

Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 2-3
Healthy adolescents in 26 centers in the USA N=3732
Some concerns
Details

Full description

EudraCT 2021-002348-57
Pfizer–BioNTech; Moderna; Oxford-AstraZeneca
Bonelli M, medRxiv, 2021

Full text
Commentary
Commentary
Non replicating viral vector

ChAdOx1 booster

BNT or mRNA booster

RCT
*
Adults under current rituximab therapy who did not develop humoral response against SARS-CoV-2 after their standard vaccination with Biontech/Pfizer or Moderna in a single center in Austria N=60
Some concerns
Details

Full description

NCT04860739, EudraCT2021-001978-37
Pfizer/BioNTech + Fosun Pharma
Borobia A M, Lancet, 2021

Full text
Commentary
RNA based vaccine

ChAd/BNT

No vaccine

RCT
Phase 2
Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain. N=676
Some concerns
Details

Full description

NCT04470427
ModernaTX
El Sahly HM, N Engl J Med, 2021
COVE

Full text
Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 3
Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US N=30415
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Frenck R, N Engl J Med, 2021

Full text
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 3
Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA N=2264
Some concerns
Details

Full description

NCT04885907
ModernaTX
Hall VG, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 4
Solid organ transplant recipients with no previous diagnosis of COVID-19 who has previously received two doses of mRNA-1273 at a single center in Canada N=120
Some concerns
Details

Full description

NCT04652102; EudraCT 2020-003998-22
CureVac AG
Kremsner P, SSRN, 2021
HERALD

Full text
Commentary
Commentary
RNA based vaccine

CVnCoV

Placebo

RCT
Phase 2-3
Adults with no history of COVID-19 in 47 centers in Belgium, Germany, The Netherlands, Spain, Argentina, Colombia, Dominican Republic, Mexico, Panama and Peru N=39529
Some concerns
Details

Full description

ChiCTR2000034825 ; NCT04523571
BioNTech RNA Pharmaceuticals
Li J, Nature Medicine, 2021

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg

BNT162b1 10 mcg

RCT
Phase 1
Healthy young adults between 18 and 55 years of age, and older adults between 65 and 85 that were SARS-COVID-2 infection-free at a single center in China. N=144
Low
Details

Full description

ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, Lancet, 2021
Com-COV

Full text
Commentary
RNA based vaccine

ChAd/BNT

BNT/ChAd

ChAd/ChAd

BNT/BNT

RCT
Phase 2
Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK N=463
Some concerns
Details

Full description

NCT04480957
Arcturus Therapeutics Inc.
Low J, medRxiv, 2021

Full text
Commentary
Commentary
RNA based vaccine

ARCT-021 1mcg

ARCT-021 5mcg

ARCT-021 7.5mcg

ARCT-021 10mcg

Placebo

RCT
Phase 1
Healthy HIV-negative adults at a single Center in Singapore. N=42
Some concerns
Details

Full description

NCT04480957
Arcturus Therapeutics Inc.
Low J, medRxiv, 2021

Full text
Commentary
Commentary
RNA based vaccine

ARCT-021 3mcg

ARCT-021 5mcg

Placebo

RCT
Phase 2
Healthy HIV-negative adults at a single Center in Singapore. N=64
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Polack F, N Engl J Med, 2020

Full text
Commentary
; Commentary
; Commentary
; Commentary
; Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43448
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Thomas S, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2-3
Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA N=44165
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Walsh E, N Engl J Med, 2020

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg D1/21

BNT162b1 20 mcg D1/21

BNT162b1

BNT162b1 100 mcg D1/21

BNT162b2 10 mcg D1/21

BNT162b2 20 mcg D1/21

BNT162b2

BNT162b1

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA N=195
Low
Details

Full description

NCT04523571 ; ChiCTR
Pfizer/BioNTech + Fosun Pharma
Zhu F, ResearchSquare, 2021

Full text
Commentary
; Commentary
RNA based vaccine

BNT126b1 10 mcg/0.5 ml 2-

BNT126b1

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China N=144
Some concerns
Details

Full description